Physician profile
Joy L Touchstone
NPI 1912019795
$11,240.43
in general payments reported to CMS, 2019-2025
39 companies · $2,657 in 2025
The $2,657 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,014 · 2020: $1,184 · 2021: $2,296 · 2022: $1,199 · 2023: $1,524 · 2024: $1,366 · 2025: $2,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,511 · Education: $35.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,511.40 |
| Education | $35.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,454.69 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $1,557.92 | 2021-2025 | Vraylar, Ubrelvy |
| Biohaven Pharmaceuticals, INC. | $1,283.01 | 2021 | |
| Lilly USA, LLC | $1,170.55 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $1,002.97 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $473.16 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.01 | 2021-2025 | Jardiance, Synjardy |
| Allergan, INC. | $276.67 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $202.86 | 2025 | Rexulti |
| Ironshore Pharmaceuticals INC. | $193.93 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $183.61 | 2019-2023 | |
| Abbott Laboratories | $179.27 | 2022-2025 | Freestyle Libre 3 |
| Biohaven Pharmaceutical Holding Company LTD. | $177.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $177.43 | 2021-2023 | |
| Endo Pharmaceuticals INC. | $171.29 | 2019-2022 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $150.10 | 2025 | Zoryve |
| Merck Sharp & Dohme LLC | $141.09 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $134.08 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $121.80 | 2019-2021 | |
| Tris Pharma INC | $113.03 | 2019 | |
| Glaxosmithkline, LLC. | $112.86 | 2025 | Arexvy |
| Amgen INC. | $96.79 | 2025 | Repatha |
| Alk-Abello, INC | $57.54 | 2023 | Grastek, Odactra, Ragwitek |
| Currax Pharmaceuticals LLC | $51.24 | 2021-2023 | Nexletol |
| Arbor Pharmaceuticals, INC. | $49.93 | 2019-2021 | |
| Cranial Technologies, INC | $49.14 | 2019-2021 | |
| Adlon Therapeutics L.P. | $42.93 | 2020 | |
| Exact Sciences Corporation | $39.26 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $34.09 | 2022 | |
| Supernus Pharmaceuticals, INC. | $32.10 | 2019-2024 | Qelbree |
| Gilead Sciences, INC. | $31.91 | 2019 | |
| Genentech USA, INC. | $31.62 | 2019 | |
| Optos, INC. | $25.15 | 2022 | |
| Renalytix Ai, INC. | $24.65 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Astellas Pharma US INC | $20.15 | 2025 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.08 | 2024 | Caplyta |
| Dexcom, INC. | $19.09 | 2025 | Dexcom G6 Transmitter |
| Therapeuticsmd, INC. | $12.67 | 2019 | |
| Medline Industries LP | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joy Touchstone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.